[43] In vitro and in Vivo models of bacterial biofilms

This chapter focuses on several methods that have been developed in the laboratory to form bacterial biofilm models in vitro and in vivo, as well as several methods developed to investigate the nature of biofilm bacteria. Ideal properties sought in an in vitro bacterial biofilm model are uniform fil...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Methods in Enzymology 1999, Vol.310, p.577-595
Hauptverfasser: Yasuda, Hiroshi, Koga, Tetsufumi, Fukuoka, Takashi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 595
container_issue
container_start_page 577
container_title Methods in Enzymology
container_volume 310
creator Yasuda, Hiroshi
Koga, Tetsufumi
Fukuoka, Takashi
description This chapter focuses on several methods that have been developed in the laboratory to form bacterial biofilm models in vitro and in vivo, as well as several methods developed to investigate the nature of biofilm bacteria. Ideal properties sought in an in vitro bacterial biofilm model are uniform film formation, uniform reproducibility, and the ability to be investigated quantitatively. However, the ability to mimic a highly complicated in vivo condition is desirable in an in vitro model. There have been relatively few reports on in vivo models of biofilm growth. One of the most difficult challenges to overcome is to devise a durable infection model. Generally, it takes several days for infected bacteria to form biofilms in an infected tissue or organ, and it takes several days longer to investigate the therapeutic effect of a drug after the biofilm mode of growth of the infected bacteria has been established. Ideally, the infection should continue in a stable condition for more than 7–10 days. Respiratory tract infections, urinary tract infections, infective endocarditis, foreign body infections, and so forth are typical infectious diseases in which the biofilm mode of bacterial growth is sometimes characteristic. Therefore, these diseases should be taken into account in making a useful in vivo experimental biofilm infection model.
doi_str_mv 10.1016/S0076-6879(99)10045-4
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69233654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0076687999100454</els_id><sourcerecordid>69233654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-c8b6959cdc91d4fc8e49ac61d531a24af0188b9b2729d556903784f18674b66a3</originalsourceid><addsrcrecordid>eNo9kMlKBDEURYMD2g6foGQluijNy5yVSOPQ0ODCYSMSUkkKIjW0leoG_95qbb2bt7iHB_cgdALkEgjIqydClCykVubcmAsghIuCb6EJCKEKZbTeRgcEKGhKAdQOmvzz--g45w8yBsaG0z20D0RwpSlMkHzj7B3PWrxKQ99h1wacWvyaVh1uuhDrjLsKl84PsU-uxmXqqlQ3-QjtVq7O8XhzD9HL3e3z9KGYP97PpjfzwnPGhsLrUhphfPAGAq-8jtw4LyEIBo5yVxHQujQlVdQEIaQhTGlegZaKl1I6dojOfv8u-u5zGfNgm5R9rGvXxm6ZrTSUMSn4CJ5uwGXZxGAXfWpc_2X_lo7A9S8wboqrFHubfYqtjyH10Q82dGmE7dq1_XFt1-6sMfbHteXsGxUJarA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69233654</pqid></control><display><type>article</type><title>[43] In vitro and in Vivo models of bacterial biofilms</title><source>ScienceDirect eBooks</source><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Yasuda, Hiroshi ; Koga, Tetsufumi ; Fukuoka, Takashi</creator><creatorcontrib>Yasuda, Hiroshi ; Koga, Tetsufumi ; Fukuoka, Takashi</creatorcontrib><description>This chapter focuses on several methods that have been developed in the laboratory to form bacterial biofilm models in vitro and in vivo, as well as several methods developed to investigate the nature of biofilm bacteria. Ideal properties sought in an in vitro bacterial biofilm model are uniform film formation, uniform reproducibility, and the ability to be investigated quantitatively. However, the ability to mimic a highly complicated in vivo condition is desirable in an in vitro model. There have been relatively few reports on in vivo models of biofilm growth. One of the most difficult challenges to overcome is to devise a durable infection model. Generally, it takes several days for infected bacteria to form biofilms in an infected tissue or organ, and it takes several days longer to investigate the therapeutic effect of a drug after the biofilm mode of growth of the infected bacteria has been established. Ideally, the infection should continue in a stable condition for more than 7–10 days. Respiratory tract infections, urinary tract infections, infective endocarditis, foreign body infections, and so forth are typical infectious diseases in which the biofilm mode of bacterial growth is sometimes characteristic. Therefore, these diseases should be taken into account in making a useful in vivo experimental biofilm infection model.</description><identifier>ISSN: 0076-6879</identifier><identifier>ISBN: 0121822117</identifier><identifier>ISBN: 9780121822118</identifier><identifier>EISSN: 1557-7988</identifier><identifier>DOI: 10.1016/S0076-6879(99)10045-4</identifier><identifier>PMID: 10547821</identifier><language>eng</language><publisher>United States: Elsevier Science &amp; Technology</publisher><subject>Animals ; Anti-Bacterial Agents - administration &amp; dosage ; Bacterial Physiological Phenomena ; Bacteriological Techniques ; Biocompatible Materials ; Biofilms - drug effects ; Biofilms - growth &amp; development ; Diffusion Chambers, Culture ; Escherichia coli - physiology ; Humans ; In Vitro Techniques ; Male ; Microscopy, Electron, Scanning ; Models, Biological ; Phagocytosis ; Pseudomonas aeruginosa - physiology ; Rats ; Rats, Wistar ; Staphylococcus epidermidis - physiology ; Stents - adverse effects</subject><ispartof>Methods in Enzymology, 1999, Vol.310, p.577-595</ispartof><rights>1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-c8b6959cdc91d4fc8e49ac61d531a24af0188b9b2729d556903784f18674b66a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0076687999100454$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,775,776,780,789,3446,3537,4010,11267,27900,27901,27902,45786,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10547821$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yasuda, Hiroshi</creatorcontrib><creatorcontrib>Koga, Tetsufumi</creatorcontrib><creatorcontrib>Fukuoka, Takashi</creatorcontrib><title>[43] In vitro and in Vivo models of bacterial biofilms</title><title>Methods in Enzymology</title><addtitle>Methods Enzymol</addtitle><description>This chapter focuses on several methods that have been developed in the laboratory to form bacterial biofilm models in vitro and in vivo, as well as several methods developed to investigate the nature of biofilm bacteria. Ideal properties sought in an in vitro bacterial biofilm model are uniform film formation, uniform reproducibility, and the ability to be investigated quantitatively. However, the ability to mimic a highly complicated in vivo condition is desirable in an in vitro model. There have been relatively few reports on in vivo models of biofilm growth. One of the most difficult challenges to overcome is to devise a durable infection model. Generally, it takes several days for infected bacteria to form biofilms in an infected tissue or organ, and it takes several days longer to investigate the therapeutic effect of a drug after the biofilm mode of growth of the infected bacteria has been established. Ideally, the infection should continue in a stable condition for more than 7–10 days. Respiratory tract infections, urinary tract infections, infective endocarditis, foreign body infections, and so forth are typical infectious diseases in which the biofilm mode of bacterial growth is sometimes characteristic. Therefore, these diseases should be taken into account in making a useful in vivo experimental biofilm infection model.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Bacterial Physiological Phenomena</subject><subject>Bacteriological Techniques</subject><subject>Biocompatible Materials</subject><subject>Biofilms - drug effects</subject><subject>Biofilms - growth &amp; development</subject><subject>Diffusion Chambers, Culture</subject><subject>Escherichia coli - physiology</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Male</subject><subject>Microscopy, Electron, Scanning</subject><subject>Models, Biological</subject><subject>Phagocytosis</subject><subject>Pseudomonas aeruginosa - physiology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Staphylococcus epidermidis - physiology</subject><subject>Stents - adverse effects</subject><issn>0076-6879</issn><issn>1557-7988</issn><isbn>0121822117</isbn><isbn>9780121822118</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMlKBDEURYMD2g6foGQluijNy5yVSOPQ0ODCYSMSUkkKIjW0leoG_95qbb2bt7iHB_cgdALkEgjIqydClCykVubcmAsghIuCb6EJCKEKZbTeRgcEKGhKAdQOmvzz--g45w8yBsaG0z20D0RwpSlMkHzj7B3PWrxKQ99h1wacWvyaVh1uuhDrjLsKl84PsU-uxmXqqlQ3-QjtVq7O8XhzD9HL3e3z9KGYP97PpjfzwnPGhsLrUhphfPAGAq-8jtw4LyEIBo5yVxHQujQlVdQEIaQhTGlegZaKl1I6dojOfv8u-u5zGfNgm5R9rGvXxm6ZrTSUMSn4CJ5uwGXZxGAXfWpc_2X_lo7A9S8wboqrFHubfYqtjyH10Q82dGmE7dq1_XFt1-6sMfbHteXsGxUJarA</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>Yasuda, Hiroshi</creator><creator>Koga, Tetsufumi</creator><creator>Fukuoka, Takashi</creator><general>Elsevier Science &amp; Technology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>1999</creationdate><title>[43] In vitro and in Vivo models of bacterial biofilms</title><author>Yasuda, Hiroshi ; Koga, Tetsufumi ; Fukuoka, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-c8b6959cdc91d4fc8e49ac61d531a24af0188b9b2729d556903784f18674b66a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Bacterial Physiological Phenomena</topic><topic>Bacteriological Techniques</topic><topic>Biocompatible Materials</topic><topic>Biofilms - drug effects</topic><topic>Biofilms - growth &amp; development</topic><topic>Diffusion Chambers, Culture</topic><topic>Escherichia coli - physiology</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Male</topic><topic>Microscopy, Electron, Scanning</topic><topic>Models, Biological</topic><topic>Phagocytosis</topic><topic>Pseudomonas aeruginosa - physiology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Staphylococcus epidermidis - physiology</topic><topic>Stents - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yasuda, Hiroshi</creatorcontrib><creatorcontrib>Koga, Tetsufumi</creatorcontrib><creatorcontrib>Fukuoka, Takashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Methods in Enzymology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yasuda, Hiroshi</au><au>Koga, Tetsufumi</au><au>Fukuoka, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>[43] In vitro and in Vivo models of bacterial biofilms</atitle><jtitle>Methods in Enzymology</jtitle><addtitle>Methods Enzymol</addtitle><date>1999</date><risdate>1999</risdate><volume>310</volume><spage>577</spage><epage>595</epage><pages>577-595</pages><issn>0076-6879</issn><eissn>1557-7988</eissn><isbn>0121822117</isbn><isbn>9780121822118</isbn><abstract>This chapter focuses on several methods that have been developed in the laboratory to form bacterial biofilm models in vitro and in vivo, as well as several methods developed to investigate the nature of biofilm bacteria. Ideal properties sought in an in vitro bacterial biofilm model are uniform film formation, uniform reproducibility, and the ability to be investigated quantitatively. However, the ability to mimic a highly complicated in vivo condition is desirable in an in vitro model. There have been relatively few reports on in vivo models of biofilm growth. One of the most difficult challenges to overcome is to devise a durable infection model. Generally, it takes several days for infected bacteria to form biofilms in an infected tissue or organ, and it takes several days longer to investigate the therapeutic effect of a drug after the biofilm mode of growth of the infected bacteria has been established. Ideally, the infection should continue in a stable condition for more than 7–10 days. Respiratory tract infections, urinary tract infections, infective endocarditis, foreign body infections, and so forth are typical infectious diseases in which the biofilm mode of bacterial growth is sometimes characteristic. Therefore, these diseases should be taken into account in making a useful in vivo experimental biofilm infection model.</abstract><cop>United States</cop><pub>Elsevier Science &amp; Technology</pub><pmid>10547821</pmid><doi>10.1016/S0076-6879(99)10045-4</doi><tpages>19</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0076-6879
ispartof Methods in Enzymology, 1999, Vol.310, p.577-595
issn 0076-6879
1557-7988
language eng
recordid cdi_proquest_miscellaneous_69233654
source ScienceDirect eBooks; MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Anti-Bacterial Agents - administration & dosage
Bacterial Physiological Phenomena
Bacteriological Techniques
Biocompatible Materials
Biofilms - drug effects
Biofilms - growth & development
Diffusion Chambers, Culture
Escherichia coli - physiology
Humans
In Vitro Techniques
Male
Microscopy, Electron, Scanning
Models, Biological
Phagocytosis
Pseudomonas aeruginosa - physiology
Rats
Rats, Wistar
Staphylococcus epidermidis - physiology
Stents - adverse effects
title [43] In vitro and in Vivo models of bacterial biofilms
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T11%3A34%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%5B43%5D%20In%20vitro%20and%20in%20Vivo%20models%20of%20bacterial%20biofilms&rft.jtitle=Methods%20in%20Enzymology&rft.au=Yasuda,%20Hiroshi&rft.date=1999&rft.volume=310&rft.spage=577&rft.epage=595&rft.pages=577-595&rft.issn=0076-6879&rft.eissn=1557-7988&rft.isbn=0121822117&rft.isbn_list=9780121822118&rft_id=info:doi/10.1016/S0076-6879(99)10045-4&rft_dat=%3Cproquest_pubme%3E69233654%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69233654&rft_id=info:pmid/10547821&rft_els_id=S0076687999100454&rfr_iscdi=true